Trials / Conditions / Recurrent Endometrial Cancer

Recurrent Endometrial Cancer

14 registered clinical trials studyying Recurrent Endometrial Cancer — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	ALPINE: Maintenance Letrozole/Abemaciclib NCT06366347	Dana-Farber Cancer Institute	Phase 2
Terminated	Study of ART0380 in Patients With Biologically Selected Solid Tumors NCT05798611	Artios Pharma Ltd	Phase 2
Withdrawn	Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch NCT05419817	Haider Mahdi	Phase 2
Terminated	Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer NCT05263492	Virginia Commonwealth University	Phase 2
Terminated	Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer NCT04906382	Floor Backes, MD	EARLY_Phase 1
Withdrawn	Pembrolizumab With Axitinib in Recurrent Endometrial Cancer NCT04197219	Case Comprehensive Cancer Center	Phase 2
Terminated	Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer NCT03277482	Dana-Farber Cancer Institute	Phase 1
Recruiting	Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Rec NCT03564340	Regeneron Pharmaceuticals	Phase 1 / Phase 2
Completed	Safety and Efficacy of Metronomic Cyclophosphamide, Metformin and Olaparib in Endometrial Cancer Patients NCT02755844	Hospices Civils de Lyon	Phase 1 / Phase 2
Completed	Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer NCT02899793	Yale University	Phase 2
Completed	Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer NCT02788708	Floor Backes	Phase 1
Completed	Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer NCT02549989	Memorial Sloan Kettering Cancer Center	Phase 2
Withdrawn	Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian Cancer NCT02117817	Rutgers, The State University of New Jersey	Phase 1
Unknown	A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Treatment for Patients With HER-2 NCT01454479	Hung-Hsueh Chou	Phase 1